Tower Research Capital (TRC)’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Tower Research Capital (TRC)’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,464	Closed	-$2K	–	6709
2022 Q2	$2K	Buy	+1,464	New	+$1.56K	﹤0.01%	5648
2022 Q1	–	Sell	-4,872	Closed	-$8K	–	6808
2021 Q4	$8K	Buy	4,872 +4,672	+2,336%	+$9.69K	﹤0.01%	4847
2021 Q3	$1K	Sell	200 -957	-83%	-$2.37K	﹤0.01%	5587
2021 Q2	$3K	Buy	1,157 +121	+12%	+$448	﹤0.01%	4979
2021 Q1	$4K	Buy	+1,036	New	+$4.22K	﹤0.01%	4831
2020 Q4	–	Sell	-385	Closed	-$2K	–	5486
2020 Q3	$2K	Buy	+385	New	+$1.55K	﹤0.01%	4641

Other funds holding MDNA

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Tower Research Capital (TRC)'s MDNA Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q3 2022, closing a stake of 1,464 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in MDNA in Q3 2020 and held it in 6 quarters. The position peaked at $8K in Q4 2021. 28 funds tracked by Wall St. Rank hold MDNA as of Q3 2022.

Tower Research Capital (TRC) reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q3 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,464 Medicenna Therapeutics Corp. Common Shares shares in Q3 2022, an estimated $2K.
Tower Research Capital (TRC) first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 6 quarters.
Tower Research Capital (TRC)'s Medicenna Therapeutics Corp. Common Shares position peaked at $8K in Q4 2021.
28 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.